US20020022056A1
(en)
|
1997-02-14 |
2002-02-21 |
Burkhard Schlutermann |
Oxacarbazepine film-coated tablets
|
MXPA04011801A
(es)
*
|
2002-05-31 |
2005-09-12 |
Desitin Arzneimittel Gmbh |
Composicion farmaceutica que contiene oxcarbazepina con liberacion controlada de la substancia activa.
|
CA2494660A1
(fr)
*
|
2002-08-06 |
2004-02-19 |
Novartis Ag |
Utilisation de carboxamides pour le traitement des acouphenes
|
GB0221956D0
(en)
*
|
2002-09-20 |
2002-10-30 |
Novartis Ag |
Organic compounds
|
RU2369393C2
(ru)
*
|
2003-09-03 |
2009-10-10 |
Новартис Аг |
Применение окскарбазепина для лечения диабетической нейропатической боли и для улучшения сна
|
AR048672A1
(es)
*
|
2004-03-22 |
2006-05-17 |
Novartis Ag |
Tabletas de desintegracion que comprenden licarbazepina
|
WO2006046105A1
(fr)
*
|
2004-10-25 |
2006-05-04 |
Ranbaxy Laboratories Limited |
Formes de dosage de l'oxcarbazepine
|
US20060252745A1
(en)
|
2005-05-06 |
2006-11-09 |
Almeida Jose L D |
Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
|
WO2007008576A2
(fr)
*
|
2005-07-08 |
2007-01-18 |
Taro Pharmaceuticals U.S.A., Inc. |
Formulation d'oxcarbazepine
|
WO2007029093A2
(fr)
*
|
2005-09-05 |
2007-03-15 |
Ranbaxy Laboratories Limited |
Formes galeniques de l'oxcarbazepine
|
AU2006337141A1
(en)
*
|
2006-01-31 |
2007-08-09 |
Teva Pharmaceutical Industries Ltd. |
Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
|
EP2029118A2
(fr)
*
|
2006-01-31 |
2009-03-04 |
Teva Pharmaceutical Industries, Inc. |
Formulation pharmaceutique d'oxcarbazepine, et sa méthode de fabrication, caractérisée en ce que l'oxcarbazepine a une distribution de la taille des particules qui est large et multi-modale
|
MX2008013675A
(es)
|
2006-04-26 |
2009-03-06 |
Supernus Pharmaceuticals Inc |
Preparaciones de liberacion controlada de oxcarbacepina que tienen perfil de liberacion sigmoidal.
|
US20080138403A1
(en)
*
|
2006-12-08 |
2008-06-12 |
Sun Pharmaceutical Industries Ltd. |
Pharmaceutical dosage forms of oxcarbazepine
|
GB0700773D0
(en)
|
2007-01-15 |
2007-02-21 |
Portela & Ca Sa |
Drug therapies
|
US8759383B2
(en)
|
2007-03-16 |
2014-06-24 |
Concert Pharmaceuticals, Inc. |
Inhibitors of cholesterol ester transfer protein
|
WO2008128166A1
(fr)
*
|
2007-04-13 |
2008-10-23 |
Concert Pharmaceuticals Inc. |
Dérivés deutériés de composés 4-(6-fluoro-1,2-benzisoxazol-3-yl) pipéridine
|
US7528131B2
(en)
*
|
2007-04-19 |
2009-05-05 |
Concert Pharmaceuticals Inc. |
Substituted morpholinyl compounds
|
EP2152689B1
(fr)
|
2007-04-25 |
2013-01-02 |
Concert Pharmaceuticals Inc. |
Analogues de cilostazol
|
AU2008247805A1
(en)
|
2007-05-01 |
2008-11-13 |
Concert Pharmaceuticals Inc. |
Naphthyl(ethyl) acetamides
|
ES2951028T3
(es)
|
2007-05-01 |
2023-10-17 |
Sun Pharmaceutical Ind Inc |
Compuestos morfinanos
|
US7973049B2
(en)
|
2007-05-01 |
2011-07-05 |
Concert Pharmaceuticals Inc. |
Morphinan compounds
|
MX341177B
(es)
|
2007-05-01 |
2016-08-10 |
Concert Pharmaceuticals Inc |
Compuestos de morfina.
|
EP2003120B9
(fr)
|
2007-06-12 |
2010-06-02 |
CoNCERT Pharmaceuticals, Inc. |
Dérivés d'azapeptide comme inhibiteurs de la protéase VIH
|
US8410124B2
(en)
*
|
2007-10-18 |
2013-04-02 |
Concert Pharmaceuticals Inc. |
Deuterated etravirine
|
EP2265334A2
(fr)
|
2008-02-29 |
2010-12-29 |
Concert Pharmaceuticals, Inc. |
Dérivés de xanthine substitués
|
US20110160253A1
(en)
*
|
2008-05-28 |
2011-06-30 |
Harbeson Scott L |
Deuterated tizanidine
|
US20100221221A1
(en)
*
|
2008-08-12 |
2010-09-02 |
Concert Pharmaceuticals Inc. |
N-phenyl-2-pyrimidineamine derivatives
|
ES2402088T3
(es)
|
2008-09-19 |
2013-04-26 |
Concert Pharmaceuticals Inc. |
Compuestos de morfinano
|
EP2365808B1
(fr)
|
2008-10-30 |
2018-01-10 |
Concert Pharmaceuticals Inc. |
Combinaison de composés de morphinane et d antidépresseur pour le traitement de l affect pseudobulbaire, des maladies neurologiques, de la douleur incurable et chronique et des lésions cérébrales
|
WO2010062690A1
(fr)
|
2008-10-30 |
2010-06-03 |
Concert Pharmaceuticals Inc. |
Combinaison de composés de morphinane et d’antidépresseur pour le traitement de l’affect pseudobulbaire, des maladies neurologiques, de la douleur incurable et chronique et des lésions cérébrales
|
US9096646B2
(en)
|
2008-11-04 |
2015-08-04 |
Anchor Therapeutics, Inc. |
CXCR4 receptor compounds
|
US20110313004A1
(en)
|
2008-12-04 |
2011-12-22 |
Concert Pharmaceuticals, Inc. |
Deuterated pyridinones
|
US20110053961A1
(en)
|
2009-02-27 |
2011-03-03 |
Concert Pharmaceuticals, Inc. |
Substituted xanthine derivatives
|
EP2408771B1
(fr)
|
2009-03-17 |
2016-11-16 |
Concert Pharmaceuticals, Inc. |
Composés de pyrazinoisoquinoline
|
WO2010138889A1
(fr)
|
2009-05-28 |
2010-12-02 |
Concert Pharmaceuticals, Inc. |
Peptides destinés au traitement des infections par le vhc
|
JP2012531419A
(ja)
|
2009-06-23 |
2012-12-10 |
コンサート ファーマシューティカルズ インコーポレイテッド |
Gaba−a受容体修飾物質としての重水素修飾されたトリアゾロピリダジン誘導体
|
US20110015154A1
(en)
*
|
2009-07-20 |
2011-01-20 |
Kellermann Gottfried H |
Supporting acetylcholine function
|
US8278460B2
(en)
|
2009-10-15 |
2012-10-02 |
Concert Pharmaceuticals, Inc. |
Substituted benzimidazoles
|
US20110098265A1
(en)
*
|
2009-10-28 |
2011-04-28 |
Neuroscience, Inc. |
Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
|
WO2011060216A1
(fr)
|
2009-11-12 |
2011-05-19 |
Concert Pharmaceuticals Inc. |
Azaindoles substitués
|
EP2536696A1
(fr)
|
2010-02-18 |
2012-12-26 |
Concert Pharmaceuticals Inc. |
Dérivés de la pyrimidine
|
WO2011106703A2
(fr)
|
2010-02-26 |
2011-09-01 |
Anchor Therapeutics, Inc. |
Composés de récepteur cxcr4
|
US8575361B2
(en)
|
2010-03-02 |
2013-11-05 |
Concert Pharmaceuticals Inc. |
Tetrahydronaphthalene derivatives
|
WO2011109464A1
(fr)
|
2010-03-02 |
2011-09-09 |
Concert Pharmaceuticals Inc. |
Dérivés de tétrahydronaphtalène deutérés
|
WO2012037060A1
(fr)
|
2010-09-13 |
2012-03-22 |
Concert Pharmaceuticals Inc. |
Azaindoles substitués
|
WO2012065028A2
(fr)
|
2010-11-11 |
2012-05-18 |
Concert Pharmaceuticals Inc. |
Tétracyclines substituées
|
WO2012079075A1
(fr)
|
2010-12-10 |
2012-06-14 |
Concert Pharmaceuticals, Inc. |
Dérivés de phtalimide deutérés
|
US8447329B2
(en)
|
2011-02-08 |
2013-05-21 |
Longsand Limited |
Method for spatially-accurate location of a device using audio-visual information
|
CA2828251A1
(fr)
|
2011-02-25 |
2012-08-30 |
Concert Pharmaceuticals, Inc. |
Derives 2-amino-naphtyridines
|
WO2012129381A1
(fr)
|
2011-03-22 |
2012-09-27 |
Concert Pharmaceuticals Inc. |
Preladenant deutéré
|
US20140213553A1
(en)
|
2011-05-03 |
2014-07-31 |
Concert Pharmaceuticals Inc. |
Carbamoylpyridone derivatives
|
WO2012154728A1
(fr)
|
2011-05-10 |
2012-11-15 |
Concert Pharmaceuticals Inc. |
N-butyl-bumétanide deutéré
|
WO2012158885A1
(fr)
|
2011-05-18 |
2012-11-22 |
Concert Pharmaceuticals Inc. |
Dérivés deutérés de l'ivacaftor
|
WO2013013052A1
(fr)
|
2011-07-19 |
2013-01-24 |
Concert Pharmaceuticals, Inc. |
Dérivés de xanthine substitués
|
CN104254540A
(zh)
|
2012-01-09 |
2014-12-31 |
安科治疗公司 |
Apj受体化合物
|
WO2013130849A1
(fr)
|
2012-02-29 |
2013-09-06 |
Concert Pharmaceuticals, Inc. |
Dérivés de phthalimide dioxopipéridinyle substitués
|
US9328113B2
(en)
|
2012-04-13 |
2016-05-03 |
Concert Pharmaceuticals, Inc. |
Substituted xanthine derivatives
|
EP2838879A1
(fr)
|
2012-04-20 |
2015-02-25 |
Concert Pharmaceuticals Inc. |
Rigosertib deutéré
|
PL3450434T3
(pl)
|
2012-06-15 |
2021-10-04 |
Concert Pharmaceuticals, Inc. |
Deuterowane pochodne ruksolitynibu
|
ES2694202T3
(es)
|
2012-07-12 |
2018-12-19 |
Concert Pharmaceuticals, Inc. |
Idebenona deuterada
|
CA2880083A1
(fr)
|
2012-08-17 |
2014-02-20 |
Concert Pharmaceuticals, Inc. |
Baricitinib deuterie
|
MY183582A
(en)
|
2012-11-19 |
2021-02-26 |
Vertex Pharmaceuticals Europe Ltd |
Deuterated cftr potentiators
|
WO2014100431A1
(fr)
|
2012-12-20 |
2014-06-26 |
Concert Pharmaceuticals, Inc. |
Inhibiteurs alk deutérés
|
WO2014100733A1
(fr)
|
2012-12-21 |
2014-06-26 |
Mayo Foundation For Medical Education And Research |
Procédés et matériaux pour le traitement de la sténose valvulaire aortique calcifiée
|
WO2014110322A2
(fr)
|
2013-01-11 |
2014-07-17 |
Concert Pharmaceuticals, Inc. |
Dérivés substitués de dioxopipéridinyl phtalimide
|
WO2014150043A1
(fr)
|
2013-03-15 |
2014-09-25 |
Concert Pharmaceuticals Inc. |
Inhibiteurs de l'enzyme udp-glucose : n-acyl-sphingosine glucosyltransférase
|
JP2016512831A
(ja)
|
2013-03-15 |
2016-05-09 |
コンサート ファーマシューティカルズ インコーポレイテッド |
重水素化されたパルボシクリブ
|
HU231191B1
(hu)
|
2013-04-15 |
2021-08-30 |
Szegedi Tudományegyetem |
Izotóp tartalmú morfin molekulák
|
EP3021861A1
(fr)
|
2013-07-18 |
2016-05-25 |
Anchor Therapeutics, Inc. |
Composés de récepteurs apj
|
WO2015009889A1
(fr)
|
2013-07-18 |
2015-01-22 |
Concert Pharmaceuticals, Inc. |
Dérivés deutériés d'intédanib et leur utilisation pour le traitement de troubles prolifératifs
|
WO2015031741A1
(fr)
|
2013-08-30 |
2015-03-05 |
Concert Pharmaceuticals, Inc. |
Thiénotriazolodiazépines substituées
|
WO2015063670A1
(fr)
*
|
2013-10-30 |
2015-05-07 |
Wockhardt Limited |
Composition orale solide a liberation modifiee comprenant de l'oxcarbazepine ou un sel pharmaceutiquement acceptable de ce compose
|
US9694017B2
(en)
|
2014-02-10 |
2017-07-04 |
Concert Pharmaceuticals, Inc. |
Substituted triazolobenzodiazepines
|
CA2981791A1
(fr)
|
2014-04-18 |
2015-10-22 |
Concert Pharmaceuticals, Inc. |
Methodes de traitement de l'hyperglycemie
|
WO2015179772A1
(fr)
|
2014-05-23 |
2015-11-26 |
Concert Pharmaceuticals, Inc. |
Composés phénylquinazolinone et phénylisoquinolinone deutérés
|
US10377718B2
(en)
|
2014-06-06 |
2019-08-13 |
Research Triangle Institute |
Apelin receptor (APJ) agonists and uses thereof
|
EP3177292B1
(fr)
|
2014-08-07 |
2020-11-25 |
Mayo Foundation for Medical Education and Research |
Composés et méthodes de traitement du cancer
|
WO2016061488A1
(fr)
|
2014-10-17 |
2016-04-21 |
Concert Pharmaceuticals, Inc. |
Inhibiteurs de réabsorption d'amines
|
WO2016073545A1
(fr)
|
2014-11-06 |
2016-05-12 |
Concert Pharmaceuticals, Inc. |
Acides benzoïques de phényloxadiazole
|
WO2016089814A1
(fr)
|
2014-12-02 |
2016-06-09 |
Concert Pharmaceuticals, Inc. |
Analogues deutériés du daclatasvir
|
WO2016105547A1
(fr)
|
2014-12-24 |
2016-06-30 |
Concert Pharmaceuticals, Inc. |
Dasabuvir deutéré
|
WO2016109795A1
(fr)
|
2014-12-31 |
2016-07-07 |
Concert Pharmaceuticals, Inc. |
Funapide et difluorofunapide deutérés
|
WO2016144830A1
(fr)
|
2015-03-06 |
2016-09-15 |
Concert Pharmaceuticals, Inc. |
Emricasan deutéré
|
EP3277647A1
(fr)
|
2015-03-31 |
2018-02-07 |
Vertex Pharmaceuticals (Europe) Limited |
Vx-661 deutéré
|
US10683305B2
(en)
|
2015-04-27 |
2020-06-16 |
Concert Pharmaceuticals, Inc. |
Deuterated OTX-015
|
WO2017020005A1
(fr)
|
2015-07-30 |
2017-02-02 |
Concert Pharmaceuticals, Inc. |
Composés de morphinane utilisés pour le traitement de l'agitation
|
WO2017020002A1
(fr)
|
2015-07-30 |
2017-02-02 |
Concert Pharmaceuticals, Inc. |
Composés de morphinane deutéré utilisés pour le traitement de l'agitation
|
US20180353500A1
(en)
|
2015-09-21 |
2018-12-13 |
Vertex Pharmaceuticals (Europe) Limited |
Administration of deuterated cftr potentiators
|
WO2017087795A1
(fr)
|
2015-11-19 |
2017-05-26 |
Concert Pharmaceuticals, Inc. |
Epi-743 deutéré
|
RU2766148C1
(ru)
|
2015-12-09 |
2022-02-08 |
Рисерч Трайэнгл Инститьют |
Улучшенные агонисты апелинового рецептора (apj) и их использование
|
WO2017147003A1
(fr)
|
2016-02-26 |
2017-08-31 |
Novobiotic Pharmaceuticals, Llc |
Nouveaux antibiotiques macrocycliques et leurs utilisations
|
JP7145080B2
(ja)
|
2016-05-04 |
2022-09-30 |
コンサート ファーマシューティカルズ インコーポレイテッド |
重水素化jak阻害剤による脱毛障害の処置
|
US10730841B2
(en)
|
2016-07-04 |
2020-08-04 |
Avanir Pharmaceuticals, Inc. |
Methods for the synthesis of deuterated dextromethorphan
|
JP7178341B2
(ja)
|
2016-08-01 |
2022-11-25 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
タンパク質およびペプチドの送達のための粒子
|
CA3054572A1
(fr)
|
2017-02-28 |
2018-09-07 |
Mayo Foundation For Medical Education And Research |
Composes et methodes de traitement du cancer
|
WO2018213609A1
(fr)
|
2017-05-17 |
2018-11-22 |
Ausubel Frederick M |
Composés antibiotiques
|
JP7228574B2
(ja)
|
2017-05-19 |
2023-02-24 |
スパーブ ウィズダム リミテッド |
レシキモドの誘導体
|
BR112020010156A2
(pt)
|
2017-11-22 |
2020-11-10 |
Concert Pharmaceuticals, Inc. |
análogos deuterados de d-serina e usos dos mesmos
|
US11243207B2
(en)
|
2018-03-29 |
2022-02-08 |
Mayo Foundation For Medical Education And Research |
Assessing and treating cancer
|
WO2021236139A1
(fr)
|
2020-05-21 |
2021-11-25 |
Concert Pharmaceuticals, Inc. |
Nouvel inhibiteur de jak deutéré et ses utilisations
|
MX2023005027A
(es)
|
2020-10-28 |
2023-07-31 |
Sun Pharmaceutical Ind Inc |
Regimenes para el tratamiento de los trastornos de la perdida de cabello con inhibidores de jak deuterados.
|
WO2023018904A1
(fr)
|
2021-08-11 |
2023-02-16 |
Concert Pharmaceuticals, Inc. |
Traitement des troubles de la chute des cheveux par des inhibiteurs de jak deutérés
|
WO2023018954A1
(fr)
|
2021-08-12 |
2023-02-16 |
Concert Pharmaceuticals, Inc. |
Traitement de troubles sensibles à l'inhibition de jak avec des promédicaments d'inhibiteurs de jak
|
WO2023215520A1
(fr)
|
2022-05-04 |
2023-11-09 |
Sun Pharmaceutical Industries, Inc. |
Régimes posologiques pour le traitement avec des inhibiteurs de jak deutérés
|